硫酸依替米星治疗下呼吸道感染的临床研究  

A clinical study of etimicin sulfae in the treatment of lower respiratory tract infection

作　　者：胡洁[1] 王素秋[1] 孙葵葵[1] 林隆[1] 李颖[1] 

机构地区：[1]首都医科大学北京天坛医院呼吸内科,北京100050

出　　处：《中国抗生素杂志》2000年第B05期25-27,共3页Chinese Journal of Antibiotics

摘　　要：采用开放对比研究比较硫酸依替米星 (ETM)与奈替米星 (NTL)以评价 ETM治疗下呼吸道感染的疗效和安全性。选择未用过抗生素治疗或虽用抗菌药物但无效的下呼吸道感染的住院病人 6 4例 ,随机分成两组 ,分别给 ETM或 NTL。结果显示 ,ETM与 NTL的有效率分别为 87.5 % (2 8/ 32 )及 90 .6 % (2 9/ 32 ) ,细菌清除率为 87.5 % (2 1/ 2 4)与 83.33% (2 0 / 2 4) ,不良反应发生率为 6 .2 5 % (2 / 32 )与 3.12 % (1/ 32 )。两组比较差异均无显著性。提示 ETM与 NTL相仿 ,抗菌谱广 ,疗效好 ,不良反应少 ,对下呼吸道感染有效且安全。Etimicin sulfate compared with Netilmicin sulfate in treating infection of lower respiratory tract were evaluated. Naive patients and some who have ever used antibiotic but without effectiveness (n=64) with lower respiratory tract infections were selected. They were randomly divided into two groups, one group was given etimicin sulfate, the other were given netilmicin sulfate. Results:Efficacy rates of etimicin sulfate group and netilmicin sulfate were 87.5%(28/32) and 90.6%(29/32); bacterial clearance rates were 87.5%(21/24) and 83.33%(20/24); and adverse drug event rates were 6.35%(2/32) and 3.12%(1/32) respectively. No significant differences was noted between etimicin sulfate and netilmicin sulfate groups. Conclusion: In treating infection of lower respiratory tract, etimicin sulfate displayed a good therapeutic efficacy,safe,low adverse drug reactions and could eradicate many kinds of bacteria, and comparable to that of netilmicin sulfate.

关 键 词：硫酸依替米星 下呼吸道感染 安全性 药物疗法 

分 类 号：R560.5[医药卫生—呼吸系统] R978.12[医药卫生—内科学]